Olinvyk is a small molecule that works as a Mu Opioid Receptor Agonist.[2] It is being used across 14 indications, with its most advanced program in Approved.[1]
Olinvyk is one of 132 small molecule programs targeting Pain. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
78 competitors in Nausea and Vomiting
Reglan
Olinvyk
Thalomid
Gemzar
Abraxane
Megace
Nereus
HSK21542
Adriamycin
Alfenta
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Oct 30, 2020
OLINVYK
NDA NDA210730
Sources
Details